Harnessing NGS-based MRD detection: Insights from a retrospective AML cohort study

Speaker and presentation summary

Sean Glenn, PhD

Director of Advanced Molecular Diagnostics Laboratory, Roswell Park Comprehensive Cancer Center, New York, USA

Dr Sean Glenn holds a B.S. in Biology and an M.S. in Molecular Biology from the University at Buffalo, where he studied genetic regulation and vascular development.

He earned a PhD in Molecular and Cellular Biology at Roswell Park Comprehensive Cancer Center, developing a mouse model to study metastatic pancreatic neuroendocrine carcinoma and its genetic drivers.

Recent publications from the speaker

1. Development and implementation of an automated and highly accurate reporting process for NGS-based clonality testing
2. Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma
3. Next-generation sequencing of PD‑L1 for predicting response to immune checkpoint inhibitors

Disclaimer

This presentation is intended for educational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the presenters individually and, unless expressly stated to the contrary, are not the opinion or position of the Oxford Gene Technology Group (OGT). OGT does not endorse or approve, and assumes no responsibility for, the content, accuracy or completeness of the information presented.

SureSeq™: For Research Use Only; Not for Use in Diagnostic Procedures.